Protease inhibitors for treatment of genotype 1 hepatitis C virus infection

BMJ (Online)

Volumn 343, Issue 7832, 2011, Pages 1060-1062

  Rowe, Ian A ^a,b   Mutimer, David J ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BOCEPREVIR; CORTICOSTEROID; ERYTHROPOIETIN; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANORECTAL DISCOMFORT; ANORECTAL DISEASE; ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; GENOTYPE; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; LONG QT SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PRURITUS; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; DRUG MONITORING; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 81555201692     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6972     Document Type: Article

References (12)

1. Thompson AJ, McHutchison JG. Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther 2009;29:689-705.
2. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63. (Pubitemid 46780082)
3. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-72. (Pubitemid 41509355)
4. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007;6:991-1000. (Pubitemid 350201789)
5. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8. (Pubitemid 46627577)
6. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77. (Pubitemid 46677938)
7. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
8. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
9. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
10. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
11. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
12. Nash KL, Bentley I, Hirschfield GM. Managing hepatitis C virus infection. BMJ 2009;338:b2366.